- Home
- LAES vs TNGX Comparison
LAES vs TNGX Comparison
Compare LAES & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAES
- TNGX
- Stock Information
- Founded
- LAES 2022
- TNGX 2014
- Country
- LAES Switzerland
- TNGX United States
- Employees
- LAES N/A
- TNGX N/A
- Industry
- LAES Semiconductors
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LAES Technology
- TNGX Health Care
- Exchange
- LAES Nasdaq
- TNGX Nasdaq
- Market Cap
- LAES 453.6M
- TNGX 351.2M
- IPO Year
- LAES N/A
- TNGX N/A
- Fundamental
- Price
- LAES $3.36
- TNGX $5.88
- Analyst Decision
- LAES Strong Buy
- TNGX Strong Buy
- Analyst Count
- LAES 1
- TNGX 6
- Target Price
- LAES $6.00
- TNGX $12.20
- AVG Volume (30 Days)
- LAES 10.7M
- TNGX 2.6M
- Earning Date
- LAES 07-22-2025
- TNGX 08-06-2025
- Dividend Yield
- LAES N/A
- TNGX N/A
- EPS Growth
- LAES N/A
- TNGX N/A
- EPS
- LAES N/A
- TNGX N/A
- Revenue
- LAES $10,981,000.00
- TNGX $40,990,000.00
- Revenue This Year
- LAES N/A
- TNGX N/A
- Revenue Next Year
- LAES N/A
- TNGX N/A
- P/E Ratio
- LAES N/A
- TNGX N/A
- Revenue Growth
- LAES N/A
- TNGX 10.09
- 52 Week Low
- LAES $0.29
- TNGX $1.03
- 52 Week High
- LAES $11.00
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- LAES 41.35
- TNGX 73.28
- Support Level
- LAES $3.31
- TNGX $5.75
- Resistance Level
- LAES $4.28
- TNGX $6.40
- Average True Range (ATR)
- LAES 0.30
- TNGX 0.50
- MACD
- LAES -0.11
- TNGX -0.03
- Stochastic Oscillator
- LAES 3.77
- TNGX 83.80
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.